This study demonstrates that stage IV CKD patients submitted to intermittent hemodialysis present an active inflammatory profile, confirmed by C-reactive protein high concentrations measured by using CRP Catalyst® device methodology, which can be used to evaluate the inflammatory activity in this treatment modality. This evidence concerns the gene CRP and chronic kidney disease.